EOFlow Seeks Global Partnership at ‘2022 German-Korean Business Forum in KAIST’
[DB Financial Investment] Diabetes market and company report on EOFlow
EOFlow Announces First Patient Enrolled in the Pivotal Study of Two-Part Wearable Artificial Pancreas “EOPatch X” on People with Type 1 Diabetes in Korea
EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE
EOFlow Announces Board Member Change to Sharpen its Focus on the US Market
EOFlow Holds a Clinical Researcher Meeting for its Two-Part Wearable Artificial Pancreas “EOPatch X” on People with Type 1 Diabetes in Korea
[Edaily news] Analysis on EOFlow company and business
[Edaily CEO interview] Reasons to invest in EOFlow
EOFlow Reports Full Year 2021 Revenue Increase of 3102% Year-Over-Year
EOFlow Successfully Raises 113.4 Billion Korean Won to Establish a Foothold to Become a Global Healthcare Leader
[MoneyToday] EOFlow with wearable drug delivery challenges obesity treatment market worth 5 billion USD
EOFlow Declares Commitment To ESG & Ethical Management Policy